Prurigo Nodularis NEMLUVIO is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (PN) who are candidates for systemic therapy.
Atopic Dermatitis NEMLUVIO is indicated for the treatment of moderate-to-severe atopic dermatitis (AD) in patients aged 12 years and older who are candidates for systemic therapy.
This website is intended for patients in Canada who have been prescribed NEMLUVIO. The contents of this website are for informational and educational purposes only and do not replace the advice of your healthcare provider. You should continue to raise any questions or concerns regarding your health or treatment with your healthcare provider.
Please verify that you are a U.S. Healthcare Professional
This information is intended for U.S. Healthcare Professionals.
You are about to leave this website for another website maintained by a third party over whom Galderma has no control. Galderma is not responsible for the content of non-Galderma websites and shall have no liability for any damages or injuries of any kind arising from such content or information.
Links to other websites are provided as a convenient resource to the users of this website only.
